Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monother ...
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Wor ...
Pulmonary Arterial Hypertension
Drug: Treprostinil Diolamine;Drug: Placebo
United Therapeutics
NULL
Completed
18 Years
75 Years
All
690
Phase 3
United States;Argentina;Australia;Austria;Brazil;Canada;Chile;China;Denmark;France;Germany;Greece;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Singapore;Sweden;Taiwan;United Kingdom United States;Argentina;Australia;Austria;Brazil;Canada;Chile;China;Denmark;France;Germany;Greece;In ...